Coronary stent thrombosis in patients with chronic renal insufficiency

Angiology

Volumn 61, Issue 3, 2010, Pages 297-303

  El Menyar, Ayman ^a,b   Hussein, Hesham ^a   Al Suwaidi, Jassim ^a,b  

^a HAMAD GENERAL HOSPITAL   (Qatar)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

Antiplatelet; Coronary; Renal insufficiency; Stent; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; COCAINE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; NONIONIC CONTRAST MEDIUM;

ACUTE CORONARY SYNDROME; ANATOMY; ANTICOAGULATION; ARTERY DISSECTION; BARE METAL STENT; BLEEDING; BRACHYTHERAPY; CHRONIC KIDNEY FAILURE; CORONARY ARTERY; CORONARY STENT; DATA BASE; DIABETES MELLITUS; DIALYSIS; DRUG ELUTING STENT; DRUG USE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERSENSITIVITY REACTION; KIDNEY DYSFUNCTION; MEDLINE; MORTALITY; PATIENT COMPLIANCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STENT THROMBOSIS; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; STENTS; TICLOPIDINE;

EID: 77949881419     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319709344574     Document Type: Review

References (71)

1. Best PJ, Lennon R., Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002 ; 39 (7). 1113-1119.
2. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001 ; 103 (15). 1967-1971.
3. Moreno R., Fernández C., Hernández R., et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005 ; 45 (6). 954-959.
4. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med. 2007 ; 356 (10). 998.
5. Prasad A., Holmes D. Update on dual antiplatelet therapy for percutaneous coronary intervention. Heart. 2009 ; 95 (11). 861-865.
6. Ho PM, Peterson ED, Wang L., et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008 ; 299 (5). 532-539.
7. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007 ; 49 (24). 2312-2317.
8. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005 ; 293 (17). 2126-2130.
9. Holmes DR Jr, Kereiakes DJ, Laskey WK, et al. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol. 2007 ; 50 (2). 109-118.
10. Spaulding C., Daemen J., Boersma E., et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007 ; 356 (10). 989-997.
11. Cutlip DE, Windecker S., Mehran R., et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 ; 115 (17). 2344-2351.
12. Kuchulakanti PK, Chu WW, Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006 ; 113 (8). 1108-1113.
13. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007 ; 369 (9562). 667-678.
14. Pfisterer M., Brunner-La Rocca HP, Buser PT, et al. BASKET-LATE Investigators: Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006 ; 48 (12). 2584-2591.
15. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of Coronary Stent Thrombosis: The Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009 ; 53 (16). 1399-1409.
16. Airoldi F., Colombo A., Morici N., et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007 ; 116 (7). 745-754.
17. Park D-W., Park S-W., Park K-H., et al. Frequency of and risk factors for stentthrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006 ; 98 (3). 352-356.
18. Lüscher TF, Steffel J., Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007 ; 115 (8). 1051-1058.
19. Cheneau E., Leborgne L., Mintz GS, et al. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation. 2003 ; 108 (1). 43-47.
20. Werner GS, Gastmann O., Ferrari M., et al. Risk factors for acute and subacute stent thrombosis after high-pressure stent implantation: a study by intracoronary ultrasound. Am Heart J. 1998 ; 135 (2 pt 1). 300-309.
21. Urban P., Gershlick AH, Guagliumi G., et al. e-Cypher Investigators. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation. 2006 ; 113 (11). 1434-1441.
22. Kotani J., Awata M., Nanto S., et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006 ; 47 (10). 2108-2111.
23. Fujii K., Carlier SG, Mintz GS, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation An intravascular ultrasound study. J Am Coll Cardiol. 2005 ; 45 (7). 995-998.
24. Cook S., Wenaweser P., Togni M., et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007 ; 115 (18). 2426-2434.
25. McKee SA, Applegate RJ, Hoyle JR, Sacrinty MT, Kutcher MA, Sane DC Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary intervention. Am Heart J. 2007 ; 154 (1). 159-164.
26. Nebeker JR, Virmani R., Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006 ; 47 (1). 175-181.
27. Ivandic BT, Sausemuth M., Ibrahim H., Giannitsis E., Gawaz M., Katus HA Dual antiplatelet drug resistance is a risk factor for cardiovascular events after percutaneous coronary intervention. Clin Chem. 2009 ; 55 (6). 1171-1176.
28. Malyszko J., Malyszko JS, Pawlak D., Pawlak K., Buczko W., Mysliwiec M. Hemostasis, platelet function and serotonin in acute and chronic renal failure. Thromb Res. 1996 ; 83 (5). 351-361.
29. Mezzano D., Tagle R., Panes O., et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, us correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost. 1996 ; 76 (3). 312-321.
30. Mezzano D., Tagle R., Pais E., et al. Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure. Thromb Res. 1997 ; 88 (6). 465-472.
31. Mason PJ, Jacobs AK, Freedman JE Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol. 2005 ; 46 (6). 986-993.
32. Wenaweser P., Dorffler-Melly J., Imboden K., et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol. 2005 ; 45 (11). 1748-1752.
33. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005 ; 45 (8). 1157-1164.
34. Barsky AA, Arora RR Clopidogrel resistance: myth or reality ? J Cardiovasc Pharmacol Therap. 2006 ; 11 (1). 47-53.
35. Hoffmann S., Ewertsen C., Klamroth R., et al. Antiplatelet therapy resistance and coronary stent thrombosis: a causal relation? Program and abstracts from the European Society of Cardiology Congress 2005; September 3-7, 2005, Stockholm, Sweden. Abstract 3751.
36. Barragan P., Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv. 2003 ; 59 (3). 295-302.
37. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002 ; 137 (7). 563-570.
38. Gaspari F., Vigan2 G., Orisio S., Bonati M., Livio M., Remuzzi G. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest. 1987 ; 79 (6). 1788-1797.
39. Baigent C., Landray M., Leaper C., et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005 ; 45 (3). 473-484.
40. Berger AK, Duval S., Krumholz HM Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003 ; 42 (2). 201-208.
41. Best PJ, Steinhubl SR, Berger PB, et al. CREDO Investigators. The Efficacy and Safety of Short- and Long-Term Dual Antiplatelet Therapy in Patients With Mild or Moderate Chronic Kidney Disease: Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. Am Heart J. 2008 ; 155 (4). 687-693.
42. Kaufman JS, Fiore L., Hasbargen JA, OgConnor TZ, Perdriset G. A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. J Thromb Thrombolysis. 2000 ; 10 (2). 127-131.
43. Taubert D., Kastrati A., Harlfinger S., et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 2004 ; 92 (2). 311-316.
44. Best PJ, Lennon R., Gersh BJ, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J. 2003 ; 146 (2). 345-350.
45. Freeman RV, Mehta RH, Al Badr W., Cooper JV, Kline-Rogers E., Eagle KA Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol. 2003 ; 41 (5). 718-724.
46. Reddan DN, OgShea JC, Sarembock IJ, et al. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol. 2003 ; 91 (1). 17-21.
47. Pinkau T., Ndrepepa G., Kastrati A., et al. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. Cardiology. 2008 ; 111 (4). 247-253.
48. Machecourt J., Danchin N., Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol. 2007 ; 50 (6). 501-508.
49. Yan BP, Duffy SJ, Clark DJ, et al. ; Melbourne Interventional Group. Rates of stent thrombosis in bare-metal versus drug-eluting stents (from a large Australian multicenter registry). Am J Cardiol. 2008 ; 101 (12). 1716-1722.
50. de la Torre-Hernández JM, Alfonso F., Hernández F., et al. ESTROFA Study Group. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol. 2008 ; 51 (10). 986-990.
51. Aoki J., Lansky AJ, Mehran R., et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents the acute catheterization and urgent intervention triage strategy trial. Circulation. 2009 ; 119 (5). 687-698.
52. Mishkel GJ, Varghese JJ, Moore AL, Aguirre F., Markwell SJ, Shelton M. Short- and long-term clinical outcomes of coronary drug-eluting stent recipients presenting with chronic renal disease. J Invasive Cardiol. 2007 ; 19 (8). 331-337.
53. Baran KW, Lasala JM, Cox DA, et al. ARRIVE Investigators. A clinical risk score for prediction of stent thrombosis. Am J Cardiol. 2008 ; 102 (5). 541-545.
54. KraÅniak A., Drozdz M., Pasowicz M., et al. Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant. 2007 ; 22 (2). 515-521.
55. Iakovou I., Agostoni P., Biondi-Zoccai G., et al. A simple risk score for prediction of thrombosis after drug-eluting stent implantation. Program and abstracts from the European Society of Cardiology Congress 2005; September 3-7, 2005, Stockholm, Sweden. Abstract 3749.
56. Nakazawa G., Tanabe K., Aoki J., et al. Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents. Catheter Cardiovasc Interv. 2007 ; 69 (6). 808-814.
57. Hassani SE, Chu WW, Wolfram RM, et al. Clinical outcomes after percutaneous coronary intervention with drug-eluting stents in dialysis patients. J Invasive Cardiol. 2006 ; 18 (6). 273-277.
58. Briguori C., Airoldi F., Chieffo A., Carlino M., Montorfano M., Colombo A. Renal function and drug-eluting stent. Int J Cardiol. 2009 [Epub ahead of print].
59. Zhu ZB, Zhang RY, Zhang Q., et al. Moderate-severe renal insufficiency is a risk factor for sirolimus-eluting stent thrombosis. The RIFT Study. Cardiology. 2009 ; 112 (3). 191-199.
60. Ishio N., Kobayashi Y., Takebayashi H., et al. Impact of drug-eluting stents on clinical and angiographic outcomes in dialysis patients. Circ J. 2007 ; 71 (10). 1525-1529.
61. Marzocchi A., Saia F., Piovaccari G., et al. Long-term safety and efficacy of drug-eluting stents: two year results of the REAL (REgistro AngiopLastiche dellgEmilia Romagna) multicenter registry. Circulation. 2007 ; 115 (25). 3181-3188.
62. Gori AM, Marcucci R., Migliorini A., et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol. 2008 ; 52 (9). 734-739.
63. Wenaweser P., Rey C., Eberli FR, et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J. 2005 ; 26 (12). 1180-1187.
64. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007 ; 115 (6). 813-818.
65. Stent thrombosis redux-the FDA perspective. N Engl J Med. 2007 ; 356 (10). 984-987.
66. Laskey WK, Yancy CW, Maisel WH Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health. Circulation. 2007 ; 115 (17). 2352-2357.
67. Cuisset T., Frere C., Quilici J., et al. Aspirin noncompliance is the major cause of ĝ€ĝ€aspirin resistancegg in patients undergoing coronary stenting. Am Heart J. 2009 ; 157 (5). 889-893.
68. Butler MJ, Eccleston D., Clark DJ, et al. Melbourne Interventional Group. The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. Am Heart J. 2009 ; 157 (5). 899-907.
69. Schömig A., Mehilli J., Holle H., et al. Statin treatment following coronary artery stenting and one-year survival. J Am Coll Cardiol. 2002 ; 40 (5). 854-861.
70. Athyros VG, Kakafika AI, Papageorgiou AA, et al. Statin-induced increase in HDL-C and renal function in coronary heart disease patients. Open Cardiovasc Med J. 2007 ; 1: 8-14.
71. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. J Clin Pathol. 2004 ; 57 (7). 728-734.